Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects - PubMed (original) (raw)

Randomized Controlled Trial

. 2017 Jan;28(1):368-375.

doi: 10.1681/ASN.2016030278. Epub 2016 Aug 18.

Affiliations

Randomized Controlled Trial

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

Hiddo J L Heerspink et al. J Am Soc Nephrol. 2017 Jan.

Abstract

Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renoprotection. We determined whether canagliflozin decreases albuminuria and reduces renal function decline independently of its glycemic effects in a secondary analysis of a clinical trial in 1450 patients with type 2 diabetes receiving metformin and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6-8 mg. End points were annual change in eGFR and albuminuria over 2 years of follow-up. Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3 ml/min per 1.73 m2 per year (95% confidence interval [95% CI], 2.8 to 3.8), 0.5 ml/min per 1.73 m2 per year (95% CI, 0.0 to 1.0), and 0.9 ml/min per 1.73 m2 per year (95% CI, 0.4 to 1.4), respectively (P<0.01 for each canagliflozin group versus glimepiride). In the subgroup of patients with baseline urinary albumin-to-creatinine ratio ≥30 mg/g, urinary albumin-to-creatinine ratio decreased more with canagliflozin 100 mg (31.7%; 95% CI, 8.6% to 48.9%; P=0.01) or canagliflozin 300 mg (49.3%; 95% CI, 31.9% to 62.2%; P<0.001) than with glimepiride. Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c of 0.81%, 0.82%, and 0.93%, respectively, at 1 year and 0.55%, 0.65%, and 0.74%, respectively, at 2 years. In conclusion, canagliflozin 100 or 300 mg/d, compared with glimepiride, slowed the progression of renal disease over 2 years in patients with type 2 diabetes, and canagliflozin may confer renoprotective effects independently of its glycemic effects.

Keywords: SGLT2; canagliflozin; diabetic nephropathy; renal function.

Copyright © 2016 by the American Society of Nephrology.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Canagliflozin slows the progression of eGFR decline in patients with type 2 diabetes compared with glimepiride. (A) Changes in eGFR in the canagliflozin and glimepiride treatment arms in the overall population, and the rate of eGFR decline per year. (B) Changes in eGFR in the canagliflozin and glimepiride treatment arms in patients with UACR≥30 mg/g, and the rate of eGFR decline per year in patients with UACR≥30 mg/g.

Figure 2.

Figure 2.

eGFR decline >30% or >40% was generally less frequent with canagliflozin compared with glimepiride.

Figure 3.

Figure 3.

Canagliflozin decreases albuminuria compared with glimepiride. (A) Changes in UACR in the canagliflozin and glimepiride treatment arms in the overall population. (B) Changes in UACR in the canagliflozin and glimepiride treatment arms in a subgroup of patients with UACR≥30 mg/g at baseline.

Comment in

Similar articles

Cited by

References

    1. American Diabetes Association : Standards of medical care in diabetes–2015. Diabetes Care 38[Suppl]: S1–S93, 2015
    1. Mudaliar S, Polidori D, Zambrowicz B, Henry RR: Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38: 2344–2353, 2015 - PubMed
    1. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941–950, 2013 - PubMed
    1. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G: Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15: 463–473, 2013 - PMC - PubMed
    1. Brewster UC, Setaro JF, Perazella MA: The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326: 15–24, 2003 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources